449 related articles for article (PubMed ID: 30918432)
1. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
[TBL] [Abstract][Full Text] [Related]
2. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
Mak LY; Ko M; To E; Wong DK; Ma JH; Hui TL; Seto WK; Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2019 Oct; 34(10):1817-1823. PubMed ID: 30786068
[TBL] [Abstract][Full Text] [Related]
3. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B.
Hsu YC; Jun T; Huang YT; Yeh ML; Lee CL; Ogawa S; Cho SH; Lin JT; Yu ML; Nguyen MH; Tanaka Y
Aliment Pharmacol Ther; 2018 Nov; 48(10):1128-1137. PubMed ID: 30306612
[TBL] [Abstract][Full Text] [Related]
4. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
5. On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy.
Murata A; Amano N; Sato S; Tsuzura H; Tomishima K; Sato S; Matsumoto K; Shimada Y; Iijima K; Genda T
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192084
[TBL] [Abstract][Full Text] [Related]
6. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
To WP; Mak LY; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
J Viral Hepat; 2019 Dec; 26(12):1473-1480. PubMed ID: 31418973
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.
Liu J; Hu HH; Lee MH; Korenaga M; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; Mizokami M; Chen CJ; Yang HI
Sci Rep; 2017 Oct; 7(1):14352. PubMed ID: 29085039
[TBL] [Abstract][Full Text] [Related]
9. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.
Mak LY; Wong DK; Seto WK; Ning Q; Cheung KS; Fung J; Lai CL; Yuen MF
Hepatol Int; 2019 Mar; 13(2):148-156. PubMed ID: 30671807
[TBL] [Abstract][Full Text] [Related]
10. Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection.
Mak LY; Wong DK; Cheung KS; Hui RW; Liu F; Fung J; Seto WK; Yuen MF
Dig Dis Sci; 2022 Nov; 67(11):5127-5136. PubMed ID: 35258755
[TBL] [Abstract][Full Text] [Related]
11. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients.
Zhu MY; Chen PZ; Li J; Yu DM; Huang D; Zhu XJ; Han Y; Chen J; Huang W; Chen YY; Gong QM; Jiang JH; Zhang DH; Zhang Y; Zhang JM; Zhang XX
J Med Virol; 2018 Apr; 90(4):721-729. PubMed ID: 29247529
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Mac-2 Binding Protein Glycosylation Isomer for Prediction of Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma.
Okuda Y; Taura K; Yoshino K; Ikeno Y; Nishio T; Yamamoto G; Tanabe K; Koyama Y; Hatano E; Tanaka S; Uemoto S
Ann Surg; 2017 Jun; 265(6):1201-1208. PubMed ID: 27355265
[TBL] [Abstract][Full Text] [Related]
13. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Nagata H; Nakagawa M; Nishimura-Sakurai Y; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Goto F; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Tojo N; Tohda S; Asahina Y; Watanabe M;
Hepatol Int; 2016 Nov; 10(6):956-964. PubMed ID: 27435935
[TBL] [Abstract][Full Text] [Related]
14. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.
Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
Clin Transl Gastroenterol; 2018 Jun; 9(6):163. PubMed ID: 29915243
[TBL] [Abstract][Full Text] [Related]
15. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi.
Baudi I; Inoue T; Tanaka Y
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023902
[TBL] [Abstract][Full Text] [Related]
16. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.
Shirabe K; Bekki Y; Gantumur D; Araki K; Ishii N; Kuno A; Narimatsu H; Mizokami M
J Gastroenterol; 2018 Jul; 53(7):819-826. PubMed ID: 29318378
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
Zhou TC; Lai X; Feng MH; Tang Y; Zhang L; Wei J
J Viral Hepat; 2018 Oct; 25(10):1172-1179. PubMed ID: 29741285
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.
Tamaki N; Kurosaki M; Loomba R; Izumi N
Ann Lab Med; 2021 Jan; 41(1):16-24. PubMed ID: 32829576
[TBL] [Abstract][Full Text] [Related]
19. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
Hsu YS; Chien RN; Yeh CT; Sheen IS; Chiou HY; Chu CM; Liaw YF
Hepatology; 2002 Jun; 35(6):1522-7. PubMed ID: 12029639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
